Latest Beta amyloid Stories
Alzheimer's disease, the primary cause of dementia in the elderly, imposes a tremendous social and economic burden on modern society.
MELBOURNE, Australia, March 31, 2014 /PRNewswire/ -- Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has today released the top line results of the 12-month Phase
--Funds Will Advance Novel Approach for Treatment of Alzheimer's Disease and Other Diseases of Protein Aggregation-- CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- NeuroPhage Pharmaceuticals,
BERLIN and BOSTON, March 20, 2014 /PRNewswire/ -- Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq(TM).
LEARN Project will Track Cognitive Change in a Comparison Group of Older Individuals, and Initiate the First Tau Imaging Study in a Longitudinal Prevention Trial CHICAGO, March 5,
Harvard stem cell scientists have successfully converted skins cells from patients with early-onset Alzheimer's into the types of neurons that are affected by the disease, making it possible for the first time to study this leading form of dementia in living human cells.
- Milestone achieved for BI's initiation of Phase 1 study in beta-secretase (BACE) inhibitor program FORT WASHINGTON, Pa., Feb.
Researchers studying peptides using the Gordon supercomputer at the San Diego Supercomputer Center (SDSC) at the University of California, San Diego have found new ways to elucidate the creation of the toxic oligomers associated with Alzheimer’s disease.
Alzheimer's disease has long been marked by progress -- but not the kind of progress the medical community seeks. It is the most common form of dementia among older Americans, and its risk increases with increasing age
Eli Lilly, the Sole Competitor in 2013, Will Be Joined by GE Healthcare, Piramal Enterprises and Navidea Biopharmaceuticals in the Next Few Years, According to Findings from Decision Resources Group